Advances in epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy for lung cancer treatment / 国际肿瘤学杂志
Journal of International Oncology
; (12): 526-529, 2013.
Article
in Zh
| WPRIM
| ID: wpr-438921
Responsible library:
WPRO
ABSTRACT
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show good efficacy for the lung cancer patients with EGFR mutations.Chemotherapy drugs are the first choices for the lung cancer patients with EGFR wild-type.In basic research,EGFR-TKIs combination with chemotherapy drugs show good synergy.But in clinical research,the timing of EGFR-TKIs combination with chemotherapy drugs is related to the efficacy.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of International Oncology
Year:
2013
Type:
Article